Drug Landscape ›
Ora-Plus ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Acute Respiratory Failure — 1 report (10%) Dehydration — 1 report (10%) Discomfort — 1 report (10%) Drug Dispensing Error — 1 report (10%) Epileptic Encephalopathy — 1 report (10%) Expired Product Administered — 1 report (10%) Hypoxia — 1 report (10%) Incorrect Dose Administered — 1 report (10%) Medication Error — 1 report (10%) Musculoskeletal Stiffness — 1 report (10%)
Source database →
Ora-Plus in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ora-Plus approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ora-Plus in United States?
Universitaire Ziekenhuizen KU Leuven is the originator. The local marketing authorisation holder may differ — check the official source linked above.